semaglutide and the amylin analog cagrilintide Cagrilintide–Semaglutide in Adults with Overweight or Obesity Type 2 Diabetes Cagrilintide lowers bodyweight through brain

Timeframe Weeks 6-12 Commonly tracked Extended-cycle community reports Notes No human RCT covers this duration

Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex

Data Availability Statement The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors

The presence of unprotected peptide bonds at both the N- and C-terminal linkages predicts that Norleual should have poor metabolic stability and rapid clearance for the circulation, properties that may limit its clinical utility

ATP Induces Disruption of Tight Junction Proteins via IL-1 Beta-Dependent MMP-9 Activation of Human Blood-Brain Barrier In Vitro